Investor

James Dondero Still Leading The Pack

Highland Capital Management co-founder James Dondero has held his own in the hedge funding game for over 30 years. His Dallas-based company has not only grown internationally into one of the most formidable hedge financial gurus, he is also one of the most philanthropic CEOs in the U.S.

Dondero started Highland Capital Management in 1993. The company offers a variety of award-winning financial products for private high-wealth citizens and corporations. Today, the company has nearly $13.5 billion in assets. The company has a number of affiliates include NexPoint Advisors and NexPoint Capital. Visit nexpointliving.com to know more about James Dondero.

Dondero began his career with Morgan Guaranty in 1984 after graduating with a finance and accounting degree from the University of Virginia. He moved on to American Express in 1985 as an accounting representative. In 1989, he left American express to work for GIS subsidiary Protective Life. While there, he transformed the company into a $2 million business.

Although he spends most of his time working financial matters, Dondero also gets involved with local philanthropic efforts. After an elderly hippo died, the Dallas Zoo closed in 2001. Dondero used his own money reopen the hippo habitat. This effort has helped Dallas residents and visitors learn more about hippos in their natural habitat.

Read: https://www.nexbank.com/james-dondero.htm

Dondero and his company has donated to the Perot Museum of Natural Science and the George H.W. Bush Museum. Dondero never had it in his mind to simply create a company simply to make money. It was always his goal to become a philanthropist. James Dondero recently hired former Woodall Rogers Park CEO Linda to become the face of the Dalls Foundation. Her expertise at the Dallas Foundation helps bridge the gap between Dondero and North Texas non profit organizations.

Mr. Dondero also serves on the board of directors of AMC Theaters, American Banknote and MGM Studios. His company has received numerous awards for excellence from Morningstar and Lipper.

Follow James on Linkedin.

Scott Rocklage: The Professor

Scott Rocklage Ph.D. has over 20 years of experience in the world of healthcare and its management and has been awarded several times for his stellar contributions to the medical world in general. He was able to join the 5 AM Ventures way back in 2003 as a partner and had become the manager in 2004.

He has been in leadership positions, and these have prepared him because currently he sits in several bards and oversees a lot of things around the country. He was the one which led to the successful approval of three new drugs:

Cubicin

  1. Telascan
  2. Omniscan

Success

Apart from that, he has entered six drugs into the clinical trials. As a leader who can inspire and lead to the betterment of the places that he serves, he has performed incredibly well. As an academic with the gift to invent, he has capitalized on that and has now registered over 30 patents that he invented or co-invented.

He conducted his research in the lab of Richard R. Schrock who won a Nobel Peace Prize in 2005. His publications which have been peer-reviewed having shown just how much of an academic he is which is something that has been proud of.

His Services

Over the years he has been in several positions that have included boards and other interests that have shaped who he is.

  • He has been the president of the Nycomed Salutar where he was also a Chief Executive Officer.

He held the R&D positions at Salutar and Catalytica.

He was serving as the board chair of Relypsa (NASDAQ: RLYP)

He was also on the board of Novira which was eventually acquired by J&J.

As of now, Scott Rocklage is serving as the Chairman on the board of the Rennovia, Cidara, and Kinestral.

  • He has been on the board of Epirasx and Pulmatrix.

Suffice to say that he has made a mark.

Alma Mater

He got his:

  • Bachelor of Science from The University of California in Chemistry.
  • He got his Ph.D. from MIT.

As an academic and an investor, he is just great.